Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study
Purpose Vaccination is an essential strategy to prevent infection in the SARS-CoV-2 pandemic. However, there are concerns about vaccine efficacy and the impact of vaccination on cancer treatment. Additionally, the emergence of novel variants may affect vaccination efficacy. This multi-center, prospe...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2022-10, Vol.195 (3), p.311-323 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 323 |
|---|---|
| container_issue | 3 |
| container_start_page | 311 |
| container_title | Breast cancer research and treatment |
| container_volume | 195 |
| creator | Terada, Mitsuo Kondo, Naoto Wanifuchi-Endo, Yumi Fujita, Takashi Asano, Tomoko Hisada, Tomoka Uemoto, Yasuaki Akiko Kato Yamanaka, Natsumi Sugiura, Hiroshi Mita, Keiko Wada, Asaka Takahashi, Eriko Saito, Kanako Yoshioka, Ryo Toyama, Tatsuya |
| description | Purpose
Vaccination is an essential strategy to prevent infection in the SARS-CoV-2 pandemic. However, there are concerns about vaccine efficacy and the impact of vaccination on cancer treatment. Additionally, the emergence of novel variants may affect vaccination efficacy. This multi-center, prospective, observational study investigated the efficacy and impact of vaccination against SARS-CoV-2 variants on treatment among breast cancer patients in Japan.
Methods
Patients with breast cancer scheduled to be vaccinated with the SARS-CoV-2 vaccine from May to November 2021 were prospectively enrolled (UMIN000045527). They were stratified into five groups according to their cancer treatment: no treatment, hormone therapy, anti-human epidermal growth factor receptor (HER)2 therapy, chemotherapy, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Serum samples for assessing serological responses were collected before the first vaccination and after the second vaccination.
Results
Eighty-five breast cancer patients were included. The overall seroconversion rate after second vaccination was 95.3% and the lowest seroconversion rate was 81.8% in the patients under chemotherapy. The overall positivity rate of neutralizing antibodies against the wild-type, α, Δ, κ, and omicron variants were 90.2%, 81.7%, 96.3%, 84.1%, and 8.5%, respectively. Among the patients under chemotherapy or CDK4/6 inhibitors, various degrees of decreased neutralizing antibody titers against SARS-CoV-2 variants were observed. Withdrawal or reduction of systemic therapy because of vaccination was observed in only one patient.
Conclusion
Our data support SARS-CoV-2 vaccination for breast cancer patients. However, a reduction in neutralizing antibody titers was suggested during chemotherapy and CDK4/6 inhibitors, raising concerns about the impact on long-term infection prevention. |
| doi_str_mv | 10.1007/s10549-022-06693-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9360656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A717098372</galeid><sourcerecordid>A717098372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c638t-4b36e9a3cd1aa9cdd0cc1a8ca8282f1f481022f725b799af9d1ba4652ad522793</originalsourceid><addsrcrecordid>eNp9kl2L1DAUhoso7rj6B7yQgCDedM1HmzReCMOwfsCC4Kq34TRNZrK0zZikA_Mf_NGmO_s1ItJCOX2f8yZ5c4riJcFnBGPxLhJcV7LElJaYc8lK-qhYkFqwUlAiHhcLTLgoeYP5SfEsxiuMsRRYPi1OWC0rUlGyKH6fW-s06D2CsUNu2IJOyFt0ufx2Wa78z5KiHWjtRkjOjyi_GkZtAkrBQBrMmJD1AbW5iulW22Y4K_E9AjRMfXKlzuUsBB-3Rie3M8i30YTdtS30KKap2z8vnljoo3lx8z0tfnw8_776XF58_fRltbwoNWdNKquWcSOB6Y4ASN11WGsCjYaGNtQSWzUkZ2IFrVshJVjZkRYqXlPoakqFZKfFh4PvdmoH082bC9CrbXADhL3y4NSxMrqNWvudkoxjXvNs8PbGIPhfk4lJDS5q0_cwGj9FRQXGjDDZiIy-_gu98lPIR54pQnldNVjeU2vojXKj9XldPZuqpSD50homaKbO_kHlpzOD03401uX_Rw1vHjRsDPRpE30_zaHHY5AeQJ1vKAZj78IgWM3Dpg7DpnKw6nrY1Nz06mGMdy2305UBdgBilsa1Cfdn_4_tHxv13-4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2712654809</pqid></control><display><type>article</type><title>Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Terada, Mitsuo ; Kondo, Naoto ; Wanifuchi-Endo, Yumi ; Fujita, Takashi ; Asano, Tomoko ; Hisada, Tomoka ; Uemoto, Yasuaki ; Akiko Kato ; Yamanaka, Natsumi ; Sugiura, Hiroshi ; Mita, Keiko ; Wada, Asaka ; Takahashi, Eriko ; Saito, Kanako ; Yoshioka, Ryo ; Toyama, Tatsuya</creator><creatorcontrib>Terada, Mitsuo ; Kondo, Naoto ; Wanifuchi-Endo, Yumi ; Fujita, Takashi ; Asano, Tomoko ; Hisada, Tomoka ; Uemoto, Yasuaki ; Akiko Kato ; Yamanaka, Natsumi ; Sugiura, Hiroshi ; Mita, Keiko ; Wada, Asaka ; Takahashi, Eriko ; Saito, Kanako ; Yoshioka, Ryo ; Toyama, Tatsuya</creatorcontrib><description>Purpose
Vaccination is an essential strategy to prevent infection in the SARS-CoV-2 pandemic. However, there are concerns about vaccine efficacy and the impact of vaccination on cancer treatment. Additionally, the emergence of novel variants may affect vaccination efficacy. This multi-center, prospective, observational study investigated the efficacy and impact of vaccination against SARS-CoV-2 variants on treatment among breast cancer patients in Japan.
Methods
Patients with breast cancer scheduled to be vaccinated with the SARS-CoV-2 vaccine from May to November 2021 were prospectively enrolled (UMIN000045527). They were stratified into five groups according to their cancer treatment: no treatment, hormone therapy, anti-human epidermal growth factor receptor (HER)2 therapy, chemotherapy, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Serum samples for assessing serological responses were collected before the first vaccination and after the second vaccination.
Results
Eighty-five breast cancer patients were included. The overall seroconversion rate after second vaccination was 95.3% and the lowest seroconversion rate was 81.8% in the patients under chemotherapy. The overall positivity rate of neutralizing antibodies against the wild-type, α, Δ, κ, and omicron variants were 90.2%, 81.7%, 96.3%, 84.1%, and 8.5%, respectively. Among the patients under chemotherapy or CDK4/6 inhibitors, various degrees of decreased neutralizing antibody titers against SARS-CoV-2 variants were observed. Withdrawal or reduction of systemic therapy because of vaccination was observed in only one patient.
Conclusion
Our data support SARS-CoV-2 vaccination for breast cancer patients. However, a reduction in neutralizing antibody titers was suggested during chemotherapy and CDK4/6 inhibitors, raising concerns about the impact on long-term infection prevention.</description><identifier>ISSN: 0167-6806</identifier><identifier>ISSN: 1573-7217</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-022-06693-2</identifier><identifier>PMID: 35941421</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibodies, Neutralizing ; Antibodies, Viral ; Breast cancer ; Breast Neoplasms - drug therapy ; Cancer ; Cancer patients ; Cancer research ; Cancer therapies ; Cancer vaccines ; Chemotherapy ; Clinical Trial ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Cyclin-dependent kinase 4 ; Cyclin-dependent kinases ; Drug therapy ; Epidemics ; Epidermal growth factor ; Female ; Health aspects ; Humans ; Immunization ; Infection ; Medicine ; Medicine & Public Health ; Observational studies ; Oncology ; Oncology, Experimental ; Patients ; Prevention ; Prospective Studies ; SARS-CoV-2 ; Seroconversion ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination ; Vaccine efficacy ; Vaccines ; Vaccines, Inactivated ; Viral Vaccines - pharmacology</subject><ispartof>Breast cancer research and treatment, 2022-10, Vol.195 (3), p.311-323</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c638t-4b36e9a3cd1aa9cdd0cc1a8ca8282f1f481022f725b799af9d1ba4652ad522793</citedby><cites>FETCH-LOGICAL-c638t-4b36e9a3cd1aa9cdd0cc1a8ca8282f1f481022f725b799af9d1ba4652ad522793</cites><orcidid>0000-0003-4713-7795</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-022-06693-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-022-06693-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35941421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terada, Mitsuo</creatorcontrib><creatorcontrib>Kondo, Naoto</creatorcontrib><creatorcontrib>Wanifuchi-Endo, Yumi</creatorcontrib><creatorcontrib>Fujita, Takashi</creatorcontrib><creatorcontrib>Asano, Tomoko</creatorcontrib><creatorcontrib>Hisada, Tomoka</creatorcontrib><creatorcontrib>Uemoto, Yasuaki</creatorcontrib><creatorcontrib>Akiko Kato</creatorcontrib><creatorcontrib>Yamanaka, Natsumi</creatorcontrib><creatorcontrib>Sugiura, Hiroshi</creatorcontrib><creatorcontrib>Mita, Keiko</creatorcontrib><creatorcontrib>Wada, Asaka</creatorcontrib><creatorcontrib>Takahashi, Eriko</creatorcontrib><creatorcontrib>Saito, Kanako</creatorcontrib><creatorcontrib>Yoshioka, Ryo</creatorcontrib><creatorcontrib>Toyama, Tatsuya</creatorcontrib><title>Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
Vaccination is an essential strategy to prevent infection in the SARS-CoV-2 pandemic. However, there are concerns about vaccine efficacy and the impact of vaccination on cancer treatment. Additionally, the emergence of novel variants may affect vaccination efficacy. This multi-center, prospective, observational study investigated the efficacy and impact of vaccination against SARS-CoV-2 variants on treatment among breast cancer patients in Japan.
Methods
Patients with breast cancer scheduled to be vaccinated with the SARS-CoV-2 vaccine from May to November 2021 were prospectively enrolled (UMIN000045527). They were stratified into five groups according to their cancer treatment: no treatment, hormone therapy, anti-human epidermal growth factor receptor (HER)2 therapy, chemotherapy, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Serum samples for assessing serological responses were collected before the first vaccination and after the second vaccination.
Results
Eighty-five breast cancer patients were included. The overall seroconversion rate after second vaccination was 95.3% and the lowest seroconversion rate was 81.8% in the patients under chemotherapy. The overall positivity rate of neutralizing antibodies against the wild-type, α, Δ, κ, and omicron variants were 90.2%, 81.7%, 96.3%, 84.1%, and 8.5%, respectively. Among the patients under chemotherapy or CDK4/6 inhibitors, various degrees of decreased neutralizing antibody titers against SARS-CoV-2 variants were observed. Withdrawal or reduction of systemic therapy because of vaccination was observed in only one patient.
Conclusion
Our data support SARS-CoV-2 vaccination for breast cancer patients. However, a reduction in neutralizing antibody titers was suggested during chemotherapy and CDK4/6 inhibitors, raising concerns about the impact on long-term infection prevention.</description><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Cancer vaccines</subject><subject>Chemotherapy</subject><subject>Clinical Trial</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Cyclin-dependent kinase 4</subject><subject>Cyclin-dependent kinases</subject><subject>Drug therapy</subject><subject>Epidemics</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infection</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Observational studies</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Patients</subject><subject>Prevention</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><subject>Seroconversion</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Vaccines, Inactivated</subject><subject>Viral Vaccines - pharmacology</subject><issn>0167-6806</issn><issn>1573-7217</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kl2L1DAUhoso7rj6B7yQgCDedM1HmzReCMOwfsCC4Kq34TRNZrK0zZikA_Mf_NGmO_s1ItJCOX2f8yZ5c4riJcFnBGPxLhJcV7LElJaYc8lK-qhYkFqwUlAiHhcLTLgoeYP5SfEsxiuMsRRYPi1OWC0rUlGyKH6fW-s06D2CsUNu2IJOyFt0ufx2Wa78z5KiHWjtRkjOjyi_GkZtAkrBQBrMmJD1AbW5iulW22Y4K_E9AjRMfXKlzuUsBB-3Rie3M8i30YTdtS30KKap2z8vnljoo3lx8z0tfnw8_776XF58_fRltbwoNWdNKquWcSOB6Y4ASN11WGsCjYaGNtQSWzUkZ2IFrVshJVjZkRYqXlPoakqFZKfFh4PvdmoH082bC9CrbXADhL3y4NSxMrqNWvudkoxjXvNs8PbGIPhfk4lJDS5q0_cwGj9FRQXGjDDZiIy-_gu98lPIR54pQnldNVjeU2vojXKj9XldPZuqpSD50homaKbO_kHlpzOD03401uX_Rw1vHjRsDPRpE30_zaHHY5AeQJ1vKAZj78IgWM3Dpg7DpnKw6nrY1Nz06mGMdy2305UBdgBilsa1Cfdn_4_tHxv13-4</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Terada, Mitsuo</creator><creator>Kondo, Naoto</creator><creator>Wanifuchi-Endo, Yumi</creator><creator>Fujita, Takashi</creator><creator>Asano, Tomoko</creator><creator>Hisada, Tomoka</creator><creator>Uemoto, Yasuaki</creator><creator>Akiko Kato</creator><creator>Yamanaka, Natsumi</creator><creator>Sugiura, Hiroshi</creator><creator>Mita, Keiko</creator><creator>Wada, Asaka</creator><creator>Takahashi, Eriko</creator><creator>Saito, Kanako</creator><creator>Yoshioka, Ryo</creator><creator>Toyama, Tatsuya</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4713-7795</orcidid></search><sort><creationdate>20221001</creationdate><title>Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study</title><author>Terada, Mitsuo ; Kondo, Naoto ; Wanifuchi-Endo, Yumi ; Fujita, Takashi ; Asano, Tomoko ; Hisada, Tomoka ; Uemoto, Yasuaki ; Akiko Kato ; Yamanaka, Natsumi ; Sugiura, Hiroshi ; Mita, Keiko ; Wada, Asaka ; Takahashi, Eriko ; Saito, Kanako ; Yoshioka, Ryo ; Toyama, Tatsuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c638t-4b36e9a3cd1aa9cdd0cc1a8ca8282f1f481022f725b799af9d1ba4652ad522793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Cancer vaccines</topic><topic>Chemotherapy</topic><topic>Clinical Trial</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Cyclin-dependent kinase 4</topic><topic>Cyclin-dependent kinases</topic><topic>Drug therapy</topic><topic>Epidemics</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infection</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Observational studies</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Patients</topic><topic>Prevention</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><topic>Seroconversion</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Vaccines, Inactivated</topic><topic>Viral Vaccines - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terada, Mitsuo</creatorcontrib><creatorcontrib>Kondo, Naoto</creatorcontrib><creatorcontrib>Wanifuchi-Endo, Yumi</creatorcontrib><creatorcontrib>Fujita, Takashi</creatorcontrib><creatorcontrib>Asano, Tomoko</creatorcontrib><creatorcontrib>Hisada, Tomoka</creatorcontrib><creatorcontrib>Uemoto, Yasuaki</creatorcontrib><creatorcontrib>Akiko Kato</creatorcontrib><creatorcontrib>Yamanaka, Natsumi</creatorcontrib><creatorcontrib>Sugiura, Hiroshi</creatorcontrib><creatorcontrib>Mita, Keiko</creatorcontrib><creatorcontrib>Wada, Asaka</creatorcontrib><creatorcontrib>Takahashi, Eriko</creatorcontrib><creatorcontrib>Saito, Kanako</creatorcontrib><creatorcontrib>Yoshioka, Ryo</creatorcontrib><creatorcontrib>Toyama, Tatsuya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terada, Mitsuo</au><au>Kondo, Naoto</au><au>Wanifuchi-Endo, Yumi</au><au>Fujita, Takashi</au><au>Asano, Tomoko</au><au>Hisada, Tomoka</au><au>Uemoto, Yasuaki</au><au>Akiko Kato</au><au>Yamanaka, Natsumi</au><au>Sugiura, Hiroshi</au><au>Mita, Keiko</au><au>Wada, Asaka</au><au>Takahashi, Eriko</au><au>Saito, Kanako</au><au>Yoshioka, Ryo</au><au>Toyama, Tatsuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>195</volume><issue>3</issue><spage>311</spage><epage>323</epage><pages>311-323</pages><issn>0167-6806</issn><issn>1573-7217</issn><eissn>1573-7217</eissn><abstract>Purpose
Vaccination is an essential strategy to prevent infection in the SARS-CoV-2 pandemic. However, there are concerns about vaccine efficacy and the impact of vaccination on cancer treatment. Additionally, the emergence of novel variants may affect vaccination efficacy. This multi-center, prospective, observational study investigated the efficacy and impact of vaccination against SARS-CoV-2 variants on treatment among breast cancer patients in Japan.
Methods
Patients with breast cancer scheduled to be vaccinated with the SARS-CoV-2 vaccine from May to November 2021 were prospectively enrolled (UMIN000045527). They were stratified into five groups according to their cancer treatment: no treatment, hormone therapy, anti-human epidermal growth factor receptor (HER)2 therapy, chemotherapy, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Serum samples for assessing serological responses were collected before the first vaccination and after the second vaccination.
Results
Eighty-five breast cancer patients were included. The overall seroconversion rate after second vaccination was 95.3% and the lowest seroconversion rate was 81.8% in the patients under chemotherapy. The overall positivity rate of neutralizing antibodies against the wild-type, α, Δ, κ, and omicron variants were 90.2%, 81.7%, 96.3%, 84.1%, and 8.5%, respectively. Among the patients under chemotherapy or CDK4/6 inhibitors, various degrees of decreased neutralizing antibody titers against SARS-CoV-2 variants were observed. Withdrawal or reduction of systemic therapy because of vaccination was observed in only one patient.
Conclusion
Our data support SARS-CoV-2 vaccination for breast cancer patients. However, a reduction in neutralizing antibody titers was suggested during chemotherapy and CDK4/6 inhibitors, raising concerns about the impact on long-term infection prevention.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35941421</pmid><doi>10.1007/s10549-022-06693-2</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-4713-7795</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2022-10, Vol.195 (3), p.311-323 |
| issn | 0167-6806 1573-7217 1573-7217 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9360656 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Antibodies, Neutralizing Antibodies, Viral Breast cancer Breast Neoplasms - drug therapy Cancer Cancer patients Cancer research Cancer therapies Cancer vaccines Chemotherapy Clinical Trial COVID-19 - prevention & control COVID-19 Vaccines Cyclin-dependent kinase 4 Cyclin-dependent kinases Drug therapy Epidemics Epidermal growth factor Female Health aspects Humans Immunization Infection Medicine Medicine & Public Health Observational studies Oncology Oncology, Experimental Patients Prevention Prospective Studies SARS-CoV-2 Seroconversion Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccine efficacy Vaccines Vaccines, Inactivated Viral Vaccines - pharmacology |
| title | Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T09%3A43%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20impact%20of%20SARS-CoV-2%20vaccination%20on%20cancer%20treatment%20for%20breast%20cancer%20patients:%20a%20multi-center%20prospective%20observational%20study&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Terada,%20Mitsuo&rft.date=2022-10-01&rft.volume=195&rft.issue=3&rft.spage=311&rft.epage=323&rft.pages=311-323&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-022-06693-2&rft_dat=%3Cgale_pubme%3EA717098372%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2712654809&rft_id=info:pmid/35941421&rft_galeid=A717098372&rfr_iscdi=true |